HCPCS Level II code Q4182 designates Transcyte billed per square centimeter as an add-on supply for biologic skin substitute applications. It matters nationally because biologic dressings are common in complex wound and burn management, influence supply and procedure-line reimbursement, and affect clinical workflows across inpatient and outpatient acute care settings.

Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and billing context, common payer coverage patterns, and typical settings where Transcyte is used.

This publication summarizes what the code represents, outlines the service line implications for hospitals and wound care centers, and highlights operational considerations for billing Transcyte as an add-on supply. It also identifies where supplemental information is needed: associated taxonomies, specific ICD-10 diagnoses, and related codes are not provided in the input and are noted as unavailable. The content is aimed at revenue cycle managers, hospital billing staff, and clinical administrators seeking a clear, national-level briefing on HCPCS Level II code Q4182.